News After phase 3 hit, Spine seeks path forward for pain drug The first phase 3 readout with Spine BioPharma's drug candidate for chronic low back pain has proved disappointing.
News Claude Science outperforms experts in protein binder task Using Claude Science, Claude agents designed high-affinity protein binders for a range of targets, outperforming human experts in some cases.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
